MMI granted AIDS patent
Medical Marketing International, the Cambridge, UK-based pharmaceutical development companyhas been granted a European patent for the AIDS therapy being developed by Viratis, MMI's joint-venture with King's and Queen Mary's Colleges, London. Patents for the AIDS therapy were granted in April for South Africa and Australia with notification of grant of the US patent received in October.
Medical Marketing International, the Cambridge, UK-based pharmaceutical development companyhas been granted a European patent for the AIDS therapy being developed by Viratis, MMI's joint-venture with King's and Queen Mary's Colleges, London. Patents for the AIDS therapy were granted in April for South Africa and Australia with notification of grant of the US patent received in October.
Dr David Brooks, business development manager at MMI, commented: 'The market for AIDS therapies is currently worth $6.3bn and is growing at 14% per annum. The Viratis team has already shown that this novel ribozyme therapy can significantly reduce the infection of human blood cells by HIV. We are, therefore, hopeful that this technology will become a major product in what is a large and growing market where resistance to existing therapies is becoming a problem. The grant of the European Patent is a further important step in the commercialisation of this therapy.'